Key words
menopause - metabolic syndrome - osteocalcin - vitamin D - osteoporosis - insulin
resistance
Schlüsselwörter
Menopause - metabolisches Syndrom - Osteocalcin - Vitamin D - Osteoporose - Insulinresistenz
Introduction
Vitamin D is synthesized in skin following exposure to UV-B radiation from sunlight.
It is a sterol group hormone rather than a vitamin and the liver and kidneys play
an active role in the subsequent synthesis of vitamin D [1]. It is called a hormone because it is synthesized in the body and connects to receptors
to perform its functions [2].
One of the most important functions of Vitamin D is the promotion of bone mineralization.
Other important functions include inhibition of cellular proliferation, induction
of terminal differentiation, inhibition of angiogenesis, induction of insulin production
and inhibition of renin production [3].
Vitamin D deficiency is the most common nutritional deficiency worldwide. Decreased
oral intake, poor nutrition, limited sun exposure, malabsorptive conditions, liver
and kidney failure and obesity may explain this high prevalence. The fact that vitamin
D levels can be low in persons with normal bone mineral density indicates that there
may be some compensatory mechanisms which prevent this deficiency from affecting bone
density [4].
The presence of a cluster of several cardiovascular risk factors such as insulin resistance,
obesity, atherogenic dyslipidemia and hypertension is referred to as metabolic syndrome.
Metabolic syndrome is characterized as one of the major health problems of postmenopausal
women and is a major cause of cardiovascular morbidity and mortality in this group
of women [5].
Studies conducted in different parts of the world have reported that the prevalence
of metabolic syndrome in postmenopausal women may be as high as 41.5% [6], [7].
Osteocalcin is a circulating biomarker that can be used to determine the quality of
bone tissue, and its production requires vitamin D [8], [9]. It is a non-collagenous protein hormone synthesized by vitamin K-dependent pathways
during bone turnover. More and more evidence is accumulating that osteocalcin, which
is secreted from osteoblasts, also plays a role in glucose and fat regulation in addition
to its role in bone mineralization and calcium homeostasis [10], [11].
Previous studies have shown a significant association between metabolic syndrome and
vitamin D levels, but the assocation with osteocalcin levels in postmenopausal patients
with normal bone mineral densities has never been previously investigated. There is
a suggestion is that the relationship between osteocalcin and vitamin D levels may
be a determinant of metabolic syndrome.
In this study we aimed to investigate the relationship between vitamin D and osteocalcin
levels in non-osteoporotic postmenopausal women who were diagnosed as having metabolic
syndrome.
Material and Methods
Study design
This cross-sectional study was performed in Zekai Tahir Burak Womenʼs Health Education
and Research Hospital, Ankara, a tertiary center in the capital city of Turkey. A
total of 191 postmenopausal women admitted to our outpatient menopause clinics for
routine clinical examination and investigation of osteoporosis were included in the
study after we obtained their informed consent. The study was carried out between
September 2013 and November 2013, which coincides with autumn in our country. Ankara
has a continental climate (average temperature: 20 – 25 °C, altitude: 891 m, latitude:
40 – 40 N, longitude: 32 – 340 E). Spring and autumn are the seasons with the most
rainfall. During the study it rained on 3 – 4 days of every month. This study was
approved by the local ethics committee and by the hospitalʼs current institutional
review board, and all study protocols were carried out in accordance with the Declaration
of Helsinki [12].
Study participants
Women with chronic diseases such as autoimmune disease, neoplasia, cancer and AIDS,
skin diseases and women who had been given vitamin D supplements or analogues (including
alphacalcidol, calciferol and cholecalciferol) over the past 12 months were excluded
from the study. None of the individuals involved in the study received any medical
treatment for bone disease. A DEXA scan was carried out in all of the women included
in the study to determine femur-neck, total femur and total L1–L4 bone density. The
T-score was more than − 2.5 for all of the investigated patients.
Metabolic syndrome was defined according to the 2006 consensus definition of the International
Diabetes Federation and includes abdominal obesity (waist circumference [WC] ≥ 80 cm;
if the BMI is > 30 kg/m2, it is assumed that central obesity is present and the waist circumference does not
need to be measured) plus two of the following criteria: hypertriglyceridemia (triglycerides
[TG] ≥ 150 mg/dL), high-density lipoprotein cholesterol (HDL-C) < 50 mg/dL, hypertension
(blood pressure ≥ 130/85 mmHg), and hyperglycemia (fasting plasma glucose ≥ 100 mg/dL)
[13]. WC was measured at the umbilicus, using a cloth tape. Blood pressure was measured
from the right arm after the patient had rested for ten minutes, using a mercury sphygmomanometer
and with the patient in a sitting position. Patients using antihypertensive drugs
were classed as hypertensive, and patients previously diagnosed with diabetes mellitus
(DM) and receiving treatment or with fasting plasma glucose > 126 mg/dl were classed
as having DM. Insulin resistance was calculated using the following formula: homeostatic
model assessment of insulin resistance (HOMA-IR) = plasma fasting insulin (mIU/L)
× plasma fasting glucose (mmol/L)/405.
Following a fast of at least eight hours, approximately 5 cc of venous blood were
taken from the antecubital vein and filled into gel tubes. Blood samples were sent
to the laboratory in a light-tight box to avoid exposure to light and centrifuged
at 4000 µg for 10 minutes. The serum was separated and analyzed immediately. Serum
levels of hormones including FSH, E2 and insulin were measured using the UniCel DxI
800 Immunoassay System (Beckman Coulter, Fullerton, CA, USA). Serum-free testosterone
levels were measured by radioimmunoassay. C-reactive protein (CRP) was determined
using a BN II nephelometer (Siemens, Erlangen, Germany). Serum levels of 25-OHD, calcium,
phosphorus, osteocalcin, deoxypyridinoline (DHP), fasting glucose, glycosylated hemoglobin
(HbA1c), and lipid profiles including HDL-C, low-density lipoprotein cholesterol (LDL-C),
total cholesterol (TC), and TG were analyzed using an AU680 Chemistry System (Beckman
Coulter) and appropriate reagents. Daily sun exposure and lifestyle, style of dress,
age, body mass index (BMI), co-morbidities, smoking status, drug use and eating habits
were recorded by the same doctor during face-to-face interviews with patients. “Covered
clothing” was the description used when the head and arms were covered but the hands
and face were not; “uncovered style of dress” was used when the head and arms were
uncovered. BMI was calculated using the formula: BMI = weight (kg)/height (m)2. Daily sun exposure times were divided into three categories as follows: A: less
than 20 minutes of daily exposure, B: daily exposure of 20 – 30 minutes, and C: more
than 30 minutes of daily exposure. All fresh blood samples were analyzed in our hospitalʼs
biochemistry laboratory.
Laboratory analysis
Serum levels of 25-OHD were measured using an enzyme-linked immunosorbent assay kit
(Immunodiagnostic AG, Leverkusen, Germany) and are presented as ng/mL. Intra-assay
and inter-assay coefficients of variation for serum 25-OHD were 8.9 and 10.6%, respectively.
Serum 25-OHD concentrations < 20 ng/mL (50 nmol/L) were classed as vitamin D deficiency.
Serum 25-OHD concentrations between 20 and 30 ng/mL were classed as vitamin D insufficiency
and a threshold value of ≥ 30 ng/mL was classed as a sufficient vitamin D status.
Serum osteocalcin was evaluated using immunometry, which only measures intact osteocalcin
molecules (Immulite 1000 Osteocalcin, DPC, Los Angeles, CA, USA).
Statistical analysis
Statistical Package for the Social Sciences, version 22.0 (SPSS Inc., Chicago, IL,
USA), was used for statistical analysis. The central limit theorem was used to determine
sample size. Quantitative data are expressed as means and standard deviations, and
quantitative data are expressed as numbers and percentages. Kolmogorov–Smirnov and
Shapiro–Wilk tests were used to assess the normal distribution of univariate variables.
Non-parametric methods were used to analyze non-normally distributed variables. Non-parametric
variables between groups were compared by Mann–Whitney U-test. Independent samples
t-test was used to compare unadjusted means between groups. Pearsonʼs χ2 test was used for categorical variables. Spearmanʼs correlation test was used to
evaluate the relationship between vitamin D, osteocalcin and other parameters. Logistic
regression analysis was also used to evaluate the risk factors that may cause metabolic
syndrome in postmenopausal women. Statistical significance was set as p < 0.05.
Results
Demographic data
The group characteristics are presented in [Table 1]. Data were differentiated into the data of women with metabolic syndrome (n = 99)
and the data of women without metabolic syndrome (n = 92). The prevalence of metabolic
syndrome was calculated as 51.8%. There was no significant difference in terms of
age between women with and without metabolic syndrome. No significant differences
were observed between groups with regard to cause of menopause, duration of menopause,
number of miscarriages, duration of sun exposure, DHP, ALP, Ca and phosphorus levels
(all p > 0.05). However, a significant difference between groups was observed with
regard to gravidity, parity and smoking status (all p < 0.05).
Table 1 Comparison of demographic data and clinical and laboratory characteristics of groups
with and without metabolic syndrome.
|
Metabolic syndrome (−) (n = 92)
|
Metabolic syndrome (+) (n = 99)
|
p
|
|
Abbreviations: BP: blood pressure, BMI: body mass index, WC: waist circumference,
HC: hip circumference, WHR: waist-to-hip ratio, hs-CRP: highly sensitive C-reactive
protein, 25-OHD: 25-hydroxyvitamin D, DHP: deoxypyridinoline, ALP: alkaline phosphates,
Ca: calcium, HDL: high-density lipoprotein, LDL: low-density lipoprotein, TG: triglyceride,
FPG: fasting plasma glucose, HOMA-IR: homeostatic model assessment of insulin resistance,
FSH: follicle-stimulating hormone, TSH: thyroid-stimulating hormone. Data are expressed
as mean ± standard deviation or * number (percentage). A p value < 0.05 is considered
statistically significant.
|
|
Demographic features
|
|
|
|
|
|
55.2 ± 6.6
|
56.8 ± 6.0
|
0.087
|
|
|
9.0 ± 6.7
|
8.6 ± 5.8
|
0.962
|
|
|
4.3 ± 3.1
|
5.3 ± 3.1
|
0.007
|
|
|
2.6 ± 2.1
|
3.0 ± 1.5
|
0.002
|
|
|
0.4 ± 0.8
|
0.6 ± 1.5
|
0.675
|
|
Cause of menopause
|
|
|
0.216
|
|
|
78 (84.8)*
|
77 (77.8)*
|
|
|
|
14 (15.2)*
|
22 (22.2)*
|
|
|
History of osteoporosis
|
5 (5.4)*
|
5 (5.1)*
|
0.905
|
|
Smoking
|
36 (39.1)*
|
18 (18.2)*
|
0.002
|
|
Alcohol
|
2 (2.2)*
|
1 (1.0)*
|
0.214
|
|
Sun exposure time (min/day)
|
41.7 ± 42.8
|
34.6 ± 46.0
|
0.055
|
|
Systolic BP (mmHg)
|
117.9 ± 14.3
|
124.7 ± 15.8
|
0.007
|
|
Diastolic BP (mmHg)
|
77.4 ± 10.8
|
81.1 ± 10.2
|
0.029
|
|
Anthropometric measurements
|
|
|
|
|
|
28.0 ± 4.9
|
32.1 ± 5.3
|
< 0.001
|
|
|
88.9 ± 10.9
|
99.2 ± 9.2
|
< 0.001
|
|
|
109.7 ± 12.1
|
116.2 ± 10.0
|
< 0.001
|
|
|
0.81 ± 0.05
|
0.85 ± 0.04
|
< 0.001
|
|
Biochemical parameters
|
|
|
|
|
|
2.6 ± 3.5
|
4.4 ± 4.4
|
< 0.001
|
|
|
20.4 ± 13.1
|
16.1 ± 11.2
|
0.013
|
|
|
5.5 ± 3.0
|
4.2 ± 2.1
|
< 0.001
|
|
|
12.0 ± 3.4
|
12.1 ± 3.4
|
0.893
|
|
|
84.4 ± 22.9
|
86.7 ± 22.0
|
0.367
|
|
|
9.8 ± 0.4
|
9.8 ± 0.4
|
0.809
|
|
|
3.8 ± 0.5
|
3.8 ± 0.5
|
0.909
|
|
|
55.3 ± 11.1
|
44.6 ± 10.0
|
< 0.001
|
|
|
145.3 ± 39.6
|
143.9 ± 40.3
|
0.807
|
|
|
130.5 ± 58.1
|
193.8 ± 89.8
|
< 0.001
|
|
|
92.6 ± 10.8
|
108.8 ± 20.7
|
< 0.001
|
|
|
5.3 ± 0.6
|
5.9 ± 0.9
|
< 0.001
|
|
|
2.0 ± 1.0
|
4.2 ± 3.4
|
< 0.001
|
|
Hormonal parameters
|
|
|
|
|
|
8.7 ± 3.8
|
15.0 ± 6.3
|
< 0.001
|
|
|
13.9 ± 7.7
|
20.7 ± 12.9
|
0.007
|
|
|
73.1 ± 29.3
|
56.5 ± 23.7
|
< 0.001
|
|
|
1.5 ± 0.6
|
1.6 ± 1.5
|
0.258
|
|
|
1.8 ± 1.2
|
1.8 ± 1.1
|
0.981
|
|
T-scores
|
|
|
|
|
|
0.2 ± 1.5
|
0.6 ± 1.2
|
0.976
|
|
|
0.3 ± 1.4
|
0.5 ± 1.2
|
0.091
|
|
|
− 1.3 ± 0.7
|
− 0.7 ± 1.6
|
0.743
|
Anthropometric and laboratory measurements
As expected, anthropometric measurements such as BMI, WC, HC and WHR were significantly
higher in the metabolic syndrome group compared to the non-metabolic syndrome group
(all p < 0.001). Serum 25-OHD levels were lower in the study group compared to controls
(20.4 ± 13.1 ng/mL vs. 16.1 ± 11.2 ng/mL; p = 0.013) and the difference was statistically
significant. [Table 2] shows the vitamin D levels in both groups according to sun exposure times. The mean
serum osteocalcin level in patients with metabolic syndrome was 4.2 ± 2.1 ng/mL, while
the level in 92 patients without metabolic syndrome was 5.5 ± 3.0 ng/mL. Osteocalcin
levels in women with metabolic syndrome were statistically significantly lower (p < 0.001).
Serum CRP values were 4.4 ± 4.4 mg/dL in patients with metabolic syndrome and 2.6 ± 3.5 mg/dL
in patients without metabolic syndrome, and the difference was statistically significant
(p < 0.001). While HDL-C levels were significantly lower in the study group, TG levels
were significantly higher in this group (p < 0.001). HOMA-IR, insulin and FPG levels
were 4.2 ± 3.4, 15.0 ± 6.3 mIU/L, and 108.8 ± 20.7 mg/dL in the metabolic syndrome
group and 2.0 ± 1.0, 8.7 ± 3.8 mIU/L, and 92.6 ± 10.8 mg/dL in the non-metabolic syndrome
group, respectively. The results of the study group were higher compared to the control
group and the difference was statistically significant (p < 0.001). The correlations
between 25-OHD and osteocalcin with other variables are shown in [Table 3]. According to the correlation analysis, there was a significant positive correlation
between 25-OHD and osteocalcin levels (r = 0.190; p = 0.008). Serum 25-OHD levels
were significantly positively correlated with daily sun exposure times (r = 0.181;
p = 0.012). An inverse correlation of 25-OHD with HDL and TG was observed for the
total group (r = 0.011, p = 0.006, respectively). On the other hand, a significant
negative correlation between osteocalcin and HbA1c and HOMA-IR values was observed in this group (p = 0.001, p = 0.048, respectively.).
Similarly, serum osteocalcin levels were negatively correlated with hs-CRP levels
(r = − 204, p = 0.003).
Table 2 Distribution of serum 25-OHD levels according to the presence or absence of metabolic
syndrome.
|
Vitamin D levels (ng/mL)
|
Metabolic syndrome (−) (n = 92)
|
Metabolic syndrome (+) (n = 99)
|
p
|
|
Data are expressed as numbers (percentages).
|
|
< 20
|
53 (57.6)
|
70 (70.7)
|
0.151
|
|
20 ≤ and < 30
|
22 (23.9)
|
18 (18.2)
|
|
≥ 30
|
17 (18.5)
|
11 (11.1)
|
|
Sun exposure time (min/day)
|
|
|
|
|
< 20
|
21 (22.8)
|
36 (36.4)
|
0.122
|
|
20 ≤ and < 30
|
5 (5.4)
|
4 (4)
|
|
≥ 30
|
66 (71.7)
|
59 (59.6)
|
Table 3 Correlation analysis between 25-OHD, osteocalcin and other parameters.
|
25-OHD
|
Osteocalcin
|
|
r
|
p
|
r
|
p
|
|
BMI: body mass index, WHR: waist-to-hip ratio, hs-CRP: highly sensitive C-reactive
protein, 25-OHD: 25-hydroxyvitamin D, DHP: deoxypyridinoline, ALP: alkaline phosphates,
Ca: calcium, HDL: high-density lipoprotein, LDL: low-density lipoprotein, TG: triglyceride,
FPG: fasting plasma glucose, HOMA-IR: homeostatic model assessment of insulin resistance,
r: Spearmanʼs correlation coefficient. A p value < 0.05 was considered statistically
significant.
|
|
25-OHD
|
1.000
|
–
|
0.190
|
0.008
|
|
Osteocalcin
|
0.190
|
0.008
|
1.000
|
–
|
|
Age
|
0.046
|
0.528
|
− 0.121
|
0.094
|
|
BMI
|
− 0.122
|
0.093
|
− 0.130
|
0.074
|
|
WHR
|
0.025
|
0.731
|
− 0.133
|
0.066
|
|
hs-CRP
|
− 0.020
|
0.779
|
− 0.214
|
0.003
|
|
DOP
|
0.245
|
0.001
|
0.340
|
0.000
|
|
ALP
|
− 0.154
|
0.034
|
0.180
|
0.013
|
|
Ca
|
0.122
|
0.093
|
0.107
|
0.140
|
|
Phosphorus
|
− 0.148
|
0.041
|
0.134
|
0.065
|
|
HDL
|
− 0.183
|
0.011
|
0.024
|
0.738
|
|
TG
|
− 0.200
|
0.006
|
0.075
|
0.304
|
|
LDL
|
0.047
|
0.522
|
0.135
|
0.063
|
|
PFG
|
− 0.121
|
0.096
|
− 0.138
|
0.058
|
|
Insulin
|
− 0.062
|
0.398
|
− 0.135
|
0.062
|
|
HbA1c
|
− 0.113
|
0.120
|
− 0.231
|
0.001
|
|
HOMA-IR
|
− 0.104
|
0.153
|
− 0.143
|
0.048
|
|
Sun exposure
|
0.181
|
0.012
|
− 0.008
|
0.908
|
|
T-score (femur-neck)
|
− 0.096
|
0.608
|
− 0.317
|
0.082
|
|
T-score (total femur)
|
− 0.149
|
0.423
|
− 0.133
|
0.477
|
|
T-score (total L1-L4)
|
0.052
|
0.779
|
0.091
|
0.622
|
Logistic regression demonstrated that hs-CRP, vitamin D, and osteocalcin levels were
risk factors for metabolic syndrome with odds ratios (95% confidence interval) of
1.121 (1.012 – 1.242), 0.958 (0.930 – 0.986), and 0.798 (0.693 – 0.919), respectively
([Table 4]).
Table 4 Logistic regression for risk factors including bone turnover markers of metabolic
syndrome.
|
Variable
|
Wald
|
p
|
Odds ratio
|
95% CI
|
|
25-OHD: 25-hydroxyvitamin D, CI: confidence interval. A p value < 0.05 is considered
statistically significant.
|
|
High sensitive CRP
|
4.822
|
0.028
|
1.121
|
1.012 – 1.242
|
|
25-OHD
|
8.561
|
0.003
|
0.958
|
0.930 – 0.986
|
|
Osteocalcin
|
9.828
|
0.002
|
0.798
|
0.693 – 0.919
|
|
Deoxypyridinoline
|
0.667
|
0.414
|
1.040
|
0.946 – 1.144
|
|
Alkaline phosphatase
|
0.034
|
0.854
|
1.001
|
0.986 – 1.017
|
|
Calcium
|
0.502
|
0.479
|
0.763
|
0.361 – 1.613
|
|
Phosphorus
|
0.075
|
0.784
|
0.924
|
0.525 – 1.627
|
Discussion
In this study, we found that osteocalcin, a bone turnover marker which is secreted
from osteoblasts, was significantly decreased in patients diagnosed as having metabolic
syndrome in the postmenopausal period with low vitamin D levels and normal bone mineral
densitometry results [14].
As both vitamin D and osteocalcin levels are low in patients with metabolic syndrome,
this suggests that these two markers may interact with each other. Osteocalcin appears
to be the agent that is actually responsible. Osteocalcin is an important factor for
both bone and energy metabolism and may be used as an additional marker with vitamin
D [15].
According to a rat study, osteocalcin-deficient knockout mice showed glucose intolerance,
increased fat mass, insulin resistance and low energy expenditure. The administration
of recombinant osteocalcin to wild-type mice resulted in an increase in blood insulin
levels and glucose tolerance, an improvement in insulin sensitivity and a decrease
in the development of obesity. Although similar relationships have been reported for
human studies, the number of studies on this has been low and most have been carried
out in men and younger people [16], [17], [18].
Our patient group consisted of postmenopausal women with metabolic syndrome. The fact
that osteocalcin levels in our study were significantly lower (p < 0.001) in individuals
with metabolic syndrome supports the findings in the literature.
The postmenopausal period is a period in which vitamin D inadequacy and deficiency
are commom [19], [20]. Vitamin D has receptors in many cells other than bone, making it a multifunctional
micronutrient [21]. Numerous studies have described a relationship between vitamin D and metabolic
syndrome; these studies have suggested that vitamin D contributes to the prevention
of atherosclerosis and foam cell formation and inhibits lipogenesis by stimulating
lipolysis in adipocytes through the elevation of calcium, and that vitamin D deficiency
is a risk factor for long-standing glucose intolerance [22]. However, a study by Kim et al. found no relationship between metabolic syndrome
and vitamin D levels [23].
Osteocalcin is more bone specific compared to vitamin D. It is accepted that vitamin
D functions more like a hormone rather than having a primary effect on bone tissue.
To investigate this relationship, a rat study was performed in vitamin D-deficient
rats which showed that osteocalcin levels were deficient at tissue level and were
similarly low in serum. When the rats were given vitamin D, osteocalcin levels increased
both in serum and in osteoblasts. Our own patient group had low levels of serum osteocalcin
as well as low levels of vitamin D, which would appear to confirm that relationship.
Based on the results of the rat study and our study, it appears that vitamin D has
an effect on bone through osteocalcin [24].
In our study, we found that vitamin D levels were lower in patients with metabolic
syndrome but the relationship between metabolic syndrome and osteocalcin turned out
to be more significant.
The fact that vitamin D levels are lower in postmenopausal patients with normal bone
mineral densities and the association with the inflammation marker CRP suggests that
treatment with vitamin D could reduce micro-inflammation in patients with metabolic
syndrome and improve metabolic parameters through the impact on osteocalcin [25], [26]. As osteocalcin plays a role in insulin resistance and fat metabolism, this is not
surprising.
We have not yet found another study in the literature that evaluates osteocalcin and
vitamin D levels together in older, non-osteoporotic, postmenopausal women. The limitations
of our study were that it was a cross-sectional study and samples were obtained during
a period when sunlight was low. The comparison of vitamin D and osteocalcin levels
in a postmenopausal population is one of the strengths of our study.
In conclusion, metabolic syndrome often occurs in the postmenopausal period, and vitamin
D deficiency is common in non-osteoporotic postmenopausal women. Vitamin D deficiency
may play an important role in the pathogenesis of metabolic syndrome. Given that vitamin
D is significantly positively correlated with osteocalcin, the administration of vitamin
D supplements to women with vitamin D deficiency may enhance osteocalcin levels. Additional
vitamin D could improve insulin resistance and decrease subclinical systemic inflammation
via osteocalcin-induced effects. In this group of patients, metabolic syndrome was
better predicted by studying osteocalcin levels rather than vitamin D levels. Further
research is necessary, but osteocalcin may be a good alternative to vitamin D in determining
an association with metabolic syndrome.
